IE890950L - Novel polypeptides having growth factor activity and nucleic acid sequences enclding the polypeptides - Google Patents

Novel polypeptides having growth factor activity and nucleic acid sequences enclding the polypeptides

Info

Publication number
IE890950L
IE890950L IE890950A IE95089A IE890950L IE 890950 L IE890950 L IE 890950L IE 890950 A IE890950 A IE 890950A IE 95089 A IE95089 A IE 95089A IE 890950 L IE890950 L IE 890950L
Authority
IE
Ireland
Prior art keywords
polypeptides
growth factor
enclding
nucleic acid
acid sequences
Prior art date
Application number
IE890950A
Other languages
English (en)
Original Assignee
Patrick O Mahony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick O Mahony filed Critical Patrick O Mahony
Publication of IE890950L publication Critical patent/IE890950L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
IE890950A 1988-03-24 1989-03-23 Novel polypeptides having growth factor activity and nucleic acid sequences enclding the polypeptides IE890950L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17265388A 1988-03-24 1988-03-24

Publications (1)

Publication Number Publication Date
IE890950L true IE890950L (en) 1989-09-24

Family

ID=22628611

Family Applications (1)

Application Number Title Priority Date Filing Date
IE890950A IE890950L (en) 1988-03-24 1989-03-23 Novel polypeptides having growth factor activity and nucleic acid sequences enclding the polypeptides

Country Status (22)

Country Link
JP (1) JPH0279981A (enExample)
KR (1) KR890014743A (enExample)
AU (2) AU3169589A (enExample)
BE (1) BE1004202A5 (enExample)
CH (1) CH681081A5 (enExample)
DE (1) DE3910084A1 (enExample)
DK (1) DK146789A (enExample)
ES (1) ES2013408A6 (enExample)
FI (1) FI891308A7 (enExample)
FR (1) FR2632321A1 (enExample)
GB (1) GB2219799B (enExample)
GR (1) GR1000876B (enExample)
HU (1) HUT50501A (enExample)
IE (1) IE890950L (enExample)
IL (1) IL89673A0 (enExample)
IT (1) IT1234961B (enExample)
LU (1) LU87489A1 (enExample)
NL (1) NL8900724A (enExample)
NO (1) NO891273D0 (enExample)
NZ (1) NZ228427A (enExample)
PT (1) PT90118B (enExample)
SE (1) SE8901031L (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
CA2037440A1 (en) * 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
US6852506B1 (en) 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
CA2249213A1 (en) * 1996-04-10 1997-10-16 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0108132A1 (en) * 1982-05-06 1984-05-16 Applied Molecular Genetics Inc. The manufacture and expression of genes for urogastrone and polypeptide analogs thereof
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
WO1985002198A1 (en) * 1983-11-01 1985-05-23 Amgen Microbial expression of type i transforming growth factor, polypeptide analogs thereof and hybrid egf/tgf polypeptides
JP2554459B2 (ja) * 1984-07-02 1996-11-13 アース製薬 株式会社 β−ウロガストロン遺伝子、対応プラスミド組換体及び対応形質転換体
FI862734A7 (fi) * 1984-10-30 1986-06-26 Oncogen Uudet polypeptidit, joilla on kasvutekijäaktiivisuutta ja nukleiinihap posekvenssit, jotka koodaavat polypeptidejä.
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
GB2210618B (en) * 1987-10-08 1991-10-16 British Bio Technology Synthetic egf gene
ES2081801T3 (es) * 1987-10-30 1996-03-16 Bristol Myers Squibb Co Plasmidos de expresion.
EP0372005A4 (en) * 1987-10-30 1990-06-26 Oncogen EXPRESSION SYSTEMS FOR THE PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS.

Also Published As

Publication number Publication date
IL89673A0 (en) 1989-09-28
PT90118B (pt) 1994-07-29
AU2990492A (en) 1993-03-04
AU3169589A (en) 1989-09-28
FI891308A0 (fi) 1989-03-20
LU87489A1 (fr) 1989-10-26
PT90118A (pt) 1989-11-10
KR890014743A (ko) 1989-10-25
SE8901031D0 (sv) 1989-03-22
SE8901031L (sv) 1989-09-25
FI891308L (fi) 1989-09-25
GB8906758D0 (en) 1989-05-10
IT1234961B (it) 1992-06-09
CH681081A5 (enExample) 1993-01-15
GR1000876B (el) 1993-03-16
BE1004202A5 (fr) 1992-10-13
NO891273D0 (no) 1989-03-22
GR890100185A (en) 1990-01-19
DK146789D0 (da) 1989-03-22
ES2013408A6 (es) 1990-05-01
NZ228427A (en) 1993-03-26
FR2632321A1 (fr) 1989-12-08
HUT50501A (en) 1990-02-28
GB2219799B (en) 1992-10-14
DK146789A (da) 1989-09-25
FI891308A7 (fi) 1989-09-25
JPH0279981A (ja) 1990-03-20
GB2219799A (en) 1989-12-20
NL8900724A (nl) 1989-10-16
IT8919917A0 (it) 1989-03-24
DE3910084A1 (de) 1989-11-16

Similar Documents

Publication Publication Date Title
CA2105998A1 (en) Human pf4a receptors and their use
DE10075006I1 (de) Verwendung von (s)(+)-2-aethoxy-4- N- 1-(2piperidino-phenyl)-3-methyl-1-butyl aminocarbonylmethyl-Benzoesaeure zur Herstellung eines Langzeitantidiabetikums
EP0846762A3 (en) Novel V31 seven transmembrane receptors
DE69709658D1 (de) Saurer katalysator in fester form und verfahren zur herstellung desselben
CA2448281A1 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
CA2316844A1 (en) Cobalt based fisher-tropsch catalyst
AU7575487A (en) Method for the preparation of proteins with factor VIII activity by microbial host cells; expression, vectors, host cells, antibodies
DE69034022D1 (de) Verfahren zur Herstellung von Fusionsproteinen
ATE212322T1 (de) Zusammensetzung aus ceriumoxid und zirkoniumoxid, verfahren zur herstellung und verwendung in katalyse
DE59002375D1 (de) Verwendung von (meth) acryloylgruppen aufweisenden polyurethanen als bindemittel fuer pulverlacke.
DE69425650D1 (de) Herstellung eines abriebbeständigen katalysatorbindemittels unter verwendung von entlaminiertem ton
IE890950L (en) Novel polypeptides having growth factor activity and nucleic acid sequences enclding the polypeptides
CA2064814A1 (en) Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
DE69925992D1 (de) VERFAHREN ZUR HERSTELLUNG VON 5-HYDROXYBENZO[b]THIOPHEN-3-CARBONSÄURE
ATE88751T1 (de) Monoklonaler antikoerper spezifisch gegen neutrophilen.
AU5633298A (en) Process for the manufacture of acrylic acid from acrolein by a redox reaction and use of a solid mixed oxides composition as redox system in the said reaction
DE69802811D1 (de) Verfahren zur herstellung von polyborazylen mesophase, polyborazylen mesophase, ihre verwendung als bn-vorläufer
EP0124998A3 (en) Crystalline zincosilicate
ATE37534T1 (de) Arylethanolhydroxylamine, verfahren zu ihrer herstellung und ihre verwendung zur leistungsfoerderung.
ES8802185A1 (es) Un metodo para preparar un anticuerpo util para la deteccion de un factor de crecimiento epidermico
ATE21393T1 (de) Thiadiazolderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DE69405928D1 (de) Synthese von Alkyl-Tert-Alkylethern unter Verwendung von Alkylsulfonsäure modifizierten Oxidkatalysatoren
ATE102921T1 (de) (alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamid, verfahren zu ihrer herstellung und ihre verwendung.
ATE60599T1 (de) Chinolin-8-carbonsaeureazolide, ein verfahren zu ihrer herstellung und ihre verwendung als herbizide.